Fascin-Centred Invasive Competence in Eutopic Endometrium: A Hypothesis-Driven Narrative Review of Endometriosis Pathogenesis and Non-Surgical Biomarker Potential

María Pilar Marín-Sánchez, Daimaris Ortega-Suárez, Álvaro Federico López-Soto, Iryna Kozak, Rebeca Benito-Villena, Marina Vives-Ramírez, Fátima Postigo-Corrales, Alejandra Isaac-Montero, Pablo Conesa‐Zamora, Ginés Luengo‐Gil
In: International Journal of Molecular Sciences · 2026 · vol. 27(16) , pp. 7234 · doi:10.3390/ijms27167234 · W7202393785
review OA: gold CC0
🔓 Open OA copy View on OpenAlex View at publisher

Abstract

Endometriosis is a chronic, oestrogen-responsive inflammatory disease characterised by endometrial-like tissue outside the uterine cavity. Because retrograde menstruation is common, lesion establishment probably requires cellular competence and a permissive ectopic microenvironment. This hypothesis-driven narrative review evaluates fascin (FSCN1) as a candidate cytoskeletal effector and considers antecedent eutopic priming versus induction after ectopic adhesion. Functional evidence was integrated with a targeted public-data screen. Donor-level reanalysis of GSE179640 found no conclusive overall eutopic case–control difference and predominantly non-epithelial expression. Exploratory analysis of GSE203191 suggested higher FSCN1 expression within a HSPA6+ stromal subcluster in diagnosed cases, without a comparable epithelial signal or detectable increase in subcluster abundance. This small post hoc analysis remains hypothesis-generating. FSCN1 was absent from the published HECA stromal/macrophage differential-expression lists and was not prioritised by the 2023 endometriosis GWAS. The current evidence therefore argues against uniform epithelial or whole-eutopic overexpression but permits a lineage-restricted stromal state. Fascin participates in autophagy- and miR-145-sensitive invasion networks, although these pathways are pleiotropic. Validation requires cycle- and lineage-resolved tissue mapping, compositional controls, matched lesions, and direct FSCN1 perturbation. Fascin should currently be regarded as a candidate multi-marker component and preclinical target, not a validated biomarker or systemic therapeutic target.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (52)

Source provenance

openalex
last seen: 2026-08-16T06:01:38.144443+00:00
License: CC0 · commercial use OK